Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Costabel

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
The European Respiratory Journal|December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
BMJ Open Respiratory Research|February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsLisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
Lymphatic Research and Biology|March 19, 2010
The International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platformMichael Nurok, Ian Eslick, Carlos R R Carvalho, et al.
Thorax|March 13, 2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisSteven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
Respiratory Research|October 29, 2009
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trialJürgen Behr, Maurits Demedts, Roland Buhl, et al.
The New England Journal of Medicine|November 25, 2005
High-dose acetylcysteine in idiopathic pulmonary fibrosisMaurits Demedts, Juergen Behr, Roland Buhl, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Chest|May 4, 2020
When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 PandemicNadera J Sweiss, Peter Korsten, Huzaefah J Syed, et al.
Annals of Internal Medicine|May 8, 2013
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialGanesh Raghu, Juergen Behr, Kevin K Brown, et al.
The European Respiratory Journal|July 27, 2014
Smoking-related idiopathic interstitial pneumoniaKevin R Flaherty, Charlene Fell, Marie-Christine Aubry, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
The European Respiratory Journal|December 10, 2015
Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsPaul W Noble, Carlo Albera, Williamson Z Bradford, et al.
BMJ Open Respiratory Research|February 3, 2016
Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsLisa Lancaster, Carlo Albera, Williamson Z Bradford, et al.
Lymphatic Research and Biology|March 19, 2010
The International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platformMichael Nurok, Ian Eslick, Carlos R R Carvalho, et al.
Thorax|March 13, 2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisSteven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
Respiratory Research|October 29, 2009
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trialJürgen Behr, Maurits Demedts, Roland Buhl, et al.
The New England Journal of Medicine|November 25, 2005
High-dose acetylcysteine in idiopathic pulmonary fibrosisMaurits Demedts, Juergen Behr, Roland Buhl, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
Chest|May 4, 2020
When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 PandemicNadera J Sweiss, Peter Korsten, Huzaefah J Syed, et al.
Annals of Internal Medicine|May 8, 2013
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialGanesh Raghu, Juergen Behr, Kevin K Brown, et al.
The European Respiratory Journal|July 27, 2014
Smoking-related idiopathic interstitial pneumoniaKevin R Flaherty, Charlene Fell, Marie-Christine Aubry, et al.
Pageof 20